897030-99-8

Basic information

• Product Name: 4-Chloro-5-iodo-6-methylpyrimidin-2-amine
• Synonyms: 2-Amino-4-chloro-5-iodo-6-methylpyrimidine;4-Chloro-5-iodo-6-methylpyrimidin-2-amine;4-Chloro-5-iodo-6-methylpyrimidin-2-amine, 2-Amino-4-chloro-5-iodo-6-methyl-1,3-diazine
• CAS NO: 897030-99-8
• Molecular Formula: C₅H₅ClIN₃
• Molecular Weight: 269.47077
• Mol File: 897030-99-8.mol

Chemical Properties

• Melting Point: 197～199℃
• Boiling Point: 406.809°C at 760 mmHg
• Flash Point: 199.831°C
• Appearance: /
• Density: 2.098g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.694
• CAS DataBase Reference: 4-Chloro-5-iodo-6-methylpyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-5-iodo-6-methylpyrimidin-2-amine(897030-99-8)
• EPA Substance Registry System: 4-Chloro-5-iodo-6-methylpyrimidin-2-amine(897030-99-8)

Safety Data

• Hazardous Substances Data: 897030-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-5-iodo-6-methylpyrimidin-2-amine is used as a chemical intermediate for the synthesis of pharmaceutical drugs. Its unique structure allows for the development of diverse compounds with potential therapeutic applications, contributing to the advancement of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Chloro-5-iodo-6-methylpyrimidin-2-amine is utilized as an intermediate in the production of agrochemicals. Its incorporation into these compounds can enhance their effectiveness in agricultural applications, such as pest control and crop protection.
Used in Organic Synthesis:
4-Chloro-5-iodo-6-methylpyrimidin-2-amine is employed in organic synthesis for the production of various functionalized pyrimidine derivatives. Its presence in these compounds allows for the creation of new chemical entities with potential applications in different fields, including pharmaceuticals and materials science.
Used in Medicinal Chemistry and Drug Discovery:
4-Chloro-5-iodo-6-methylpyrimidin-2-amine may have potential applications in the field of medicinal chemistry and drug discovery. Its unique structural features make it a valuable building block for the development of diverse compounds with potential pharmaceutical and agricultural applications, contributing to the discovery of new drugs and agrochemicals.

InChI:InChI=1/C5H5ClIN3/c1-2-3(7)4(6)10-5(8)9-2/h1H3,(H2,8,9,10)

Upstream product

• 3977-29-5 2-amino-6-methyl-3H-pyrimidin-4-one 
• 5600-21-5 2-amino-6-methyl-4-chloropyrimidine 

Downstream Products

• 99586-66-0 2-amino-4-chloro-6-methylpyrimidine-5-carbonitrile 
• 1552301-45-7 2-(trans-4-(2-amino-6-(6-methoxypyridin-3-yl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyloxy)ethanol 
• 1552301-43-5 2-(trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(6-methoxypyridin-3-yl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyloxy)ethanol 
• 1552301-40-2 C₂₅H₂₉N₅O₂ 
• 1552301-38-8 trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-((6-methoxypyridin-3-yl)ethynyl)-6-methylpyrimidin-4-ylamino)cyclohexanol 
• 1552301-36-6 trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-ethynyl-6-methylpyrimidin-4-ylamino)cyclohexanol 
• 1552301-32-2 2-(trans-4-(2-amino-5-(6-methoxypyridin-3-yl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyloxy)ethanol 
• 1552301-28-6 2-(trans-4-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyloxy)ethanol 
• 1552301-26-4 2-(trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyloxy)ethanol 
• 1552301-24-2 trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol 
• 1552301-22-0 trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methyl-5-((trimethylsilyl)ethynyl)pyrimidin-4-ylamino)cyclohexanol 
• 1552301-20-8 trans-4-(2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-iodo-6-methylpyrimidin-4-ylamino)cyclohexanol 
• 1425042-41-6 (S)-2-amino-4-((1-(8-chloro-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)amino)-6-methylpyrimidine-5-carbonitrile 

Relevant articles and documents

PYRAZOLOPYRIMIDINE COMPOUND AS PI3K INHIBITOR AND USE THEREOF

The present application relates to a pyrazolopyrimidine compound of Formula (I) and a pharmaceutically acceptable salt thereof. Such compounds can be used to inhibit the activity of a lipid kinase PI3K, and can also be used to treat diseases mediated by P

PYRIMIDINES AND USES THEREOF

The various examples presented herein are directed to compounds of the Formula: wherein R1-R5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines

Activation of human toll-like receptor-8 (TLR8) evokes a distinct cytokine profile favoring the generation of Type 1 helper T cells. A multiplexed high-throughput screen had led to the identification of N4-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agonist, and a detailed structure-activity relationship study of this chemotype was undertaken. A butyl substituent at N4 was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to losses in potency, as did the introduction of aromatic bulk. Drawing from our previous structure-based design, several 5-alkylamino derivatives were evaluated. Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N4-butyl-6-methylpyrimidine-2,4-diamine. This compound potently induced Th1-biasing IFN-γ and IL-12 in human blood, but lower levels of the proinflammatory cytokines IL-1β, IL-6, and IL-8. These results suggest that the inflammatory and reactogenic propensities of this compound could be considerably more favorable than other TLR8 agonists under evaluation.

Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors

Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is one of the most intensively studied approaches to cancer therapy. Rational design led to the identification of novel 7-amino-5-methyl-1,6-naph

5-Alkynyl-pyridines

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification

NEW 5-ALKYNYL-PYRIDINES

5-alkynyl-pyridine of general formula (I) which are inhibitors of the activity of PI3K alpha, and their use in the treatment of diseases characterized by excessive or abnormal cell proliferation, such as cancer.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of P13Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR

The invention is directed to Compounds of Formula (I): optionally as a single stereoisomer or mixture of stereoisomers thereof, and additionally optionally as a pharmaceutically acceptable salt thereof; as well as methods of making and using the compounds.